About this episode
Sodium Glucose Co-Transporter-2 Inhibitors, a medication class for the treatment of diabetes, is now showing benefits in other medical conditions, like heart failure and kidney disease. Is this a class effect? Additional Resources/References: McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis . JAMA Cardiol. Published online October 07, 2020. doi:10.1001/jamacardio.2020.4511 This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today! See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices